Published in Support Care Cancer on June 03, 2003
Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90
Multiple Myeloma, Version 2.2016. J Natl Compr Canc Netw (2015) 0.81
Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy. Support Care Cancer (2004) 0.78
Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women. Clin Interv Aging (2007) 0.75
Ibandronate for prevention and treatment of glucocorticoid-induced osteoporosis in rabbits. Rheumatol Int (2011) 0.75
Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood (2000) 3.60
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol (2001) 2.72
Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med (1990) 2.43
Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med (1993) 2.20
Allocation of patients to treatment in clinical trials. Biometrics (1979) 2.13
Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med (1993) 1.23
Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf (1999) 1.09
Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol (1988) 1.07
Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol (1992) 0.90
Renal failure associated with intravenous diphosphonates. Lancet (1983) 0.88
Acute intravenous infusion of disodium dihydrogen (1-hydroxyethylidene)diphosphonate: mechanism of toxicity. J Pharm Sci (1984) 0.88
Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab (1994) 0.87
Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer (1997) 0.85
Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res (1996) 0.84
Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol (1996) 0.80
Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res (2000) 0.76
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Vitamin-D-receptor-gene polymorphisms and change in lumbar-spine bone mineral density. Lancet (1995) 3.82
Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1998) 2.81
Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporos Int (2012) 2.48
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab (1992) 2.42
Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab (1991) 2.27
Bone strength and its determinants. Osteoporos Int (2003) 2.25
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol (2003) 2.16
Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend. Bone (2007) 1.88
Gain in bone mineral mass in prepubertal girls 3.5 years after discontinuation of calcium supplementation: a follow-up study. Lancet (2001) 1.82
Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest (1997) 1.81
Development of hearing loss during long-term exposure to occupational noise. A 20-year follow-up study. Scand Audiol (1986) 1.77
A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int (2002) 1.70
Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest (1997) 1.70
Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int (2012) 1.58
Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer (2000) 1.56
Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol (2007) 1.52
Peak bone mass. Osteoporos Int (1994) 1.52
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia (2007) 1.48
Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int (2002) 1.47
Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int (2008) 1.45
Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int (2009) 1.44
Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis (2013) 1.40
Familial resemblance for bone mineral mass is expressed before puberty. J Clin Endocrinol Metab (1998) 1.39
The activity of the renin-angiotensin-aldosterone system before and during submaximal bicycle exercise in relation to circulatory catecholamines in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1990) 1.39
Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther (1999) 1.35
Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol (2009) 1.32
A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res (1996) 1.27
Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol (2013) 1.27
What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis? Ann Rheum Dis (2013) 1.25
FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int (2009) 1.19
An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporos Int (2002) 1.15
Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos Int (1994) 1.15
Preferential low bone mineral density of the femoral neck in patients with a recent fracture of the proximal femur. Osteoporos Int (1991) 1.14
Adherence to treatment of osteoporosis: a need for study. Osteoporos Int (2007) 1.13
Pulmonary function in workers exposed to diesel exhausts: the effect of control measures. Am J Ind Med (1991) 1.12
Sodium-dependent phosphate transport inhibited by parathyroid hormone and cyclic AMP stimulation in an opossum kidney cell line. J Biol Chem (1986) 1.10
Benefits of oral protein supplementation in elderly patients with fracture of the proximal femur. J Am Coll Nutr (1992) 1.09
Tools in the assessment of sarcopenia. Calcif Tissue Int (2013) 1.09
Asynchrony between the rates of standing height gain and bone mass accumulation during puberty. Osteoporos Int (1997) 1.06
Treatment of osteoporosis in men. Bone (2012) 1.06
Evaluation of the age-adjusted incidence of hip fractures between urban and rural areas: the difference is not related to the prevalence of institutions for the elderly. Osteoporos Int (2002) 1.06
The influence of pubertal timing on bone mass acquisition: a predetermined trajectory detectable five years before menarche. J Clin Endocrinol Metab (2009) 1.06
Morphology of the vestibular nerve. II. The number of myelinated vestibular nerve fibers in man at various ages. Acta Otolaryngol (1974) 1.05
Weight-bearing bones are more sensitive to physical exercise in boys than in girls during pre- and early puberty: a cross-sectional study. Osteoporos Int (2008) 1.05
Vitamin D supplementation during infancy is associated with higher bone mineral mass in prepubertal girls. J Clin Endocrinol Metab (1999) 1.04
Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer (2004) 1.04
Immunocytochemical detection of phosphatidylinositol 4,5-bisphosphate localization sites within the nucleus. J Histochem Cytochem (1995) 1.04
Genetic aspects of osteoporosis. Curr Opin Rheumatol (1999) 1.04
Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium levels after parathyroidectomy. Am J Med (1985) 1.03
Do dietary calcium and age explain the controversy surrounding the relationship between bone mineral density and vitamin D receptor gene polymorphisms? J Bone Miner Res (1998) 1.03
Malleolar fractures: nonoperative versus operative treatment. A controlled study. Clin Orthop Relat Res (1985) 1.02
Effect of estrogen deficiency on cancellous and cortical bone structure and strength of the femoral neck in rats. Calcif Tissue Int (1997) 1.02
Vitamin D receptor gene start codon polymorphisms (FokI) and bone mineral density: interaction with age, dietary calcium, and 3'-end region polymorphisms. J Bone Miner Res (1998) 1.02
Protein undernutrition-induced bone loss is associated with decreased IGF-I levels and estrogen deficiency. J Bone Miner Res (2000) 1.01
High-resolution detection of newly synthesized DNA by anti-bromodeoxyuridine antibodies identifies specific chromatin domains. J Histochem Cytochem (1990) 1.01
Reversal of the hip fracture secular trend is related to a decrease in the incidence in institution-dwelling elderly women. Osteoporos Int (2008) 1.00
Sequential and precise in vivo measurement of bone mineral density in rats using dual-energy x-ray absorptiometry. J Bone Miner Res (1992) 1.00
A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int (2003) 1.00
The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int (2004) 1.00
Vestibular sensory epithelia. Arch Otolaryngol (1974) 1.00
Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone (1988) 1.00
Longitudinal measurement of regional and whole body bone mass in young healthy adults. Osteoporos Int (1994) 0.99
Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int (2011) 0.99
Post-fracture management of patients with hip fracture: a perspective. Curr Med Res Opin (2008) 0.99
A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B. Clin Exp Immunol (1999) 0.98
A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int (2011) 0.98
Does the mini nutritional assessment predict hospitalization outcomes in older people? Age Ageing (2001) 0.98
Macula utriculi and macula sacculi in the squirrel monkey. Acta Otolaryngol Suppl (1972) 0.98
The mastoid air cell system in ear surgery. Arch Otolaryngol (1978) 0.96
Comment on Freemantle et al.: Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments. Osteoporos Int (2013) 0.96
Relationship between bone mineral density and dietary intakes in the elderly. Osteoporos Int (1993) 0.96
Dairy foods and osteoporosis: an example of assessing the health-economic impact of food products. Osteoporos Int (2012) 0.96
Urinary screening for potentially genotoxic exposures in a chemical industry. Br J Ind Med (1985) 0.95
Hemorrhage in the floor of the mouth during implant placement in the edentulous mandible: a case report. Int J Oral Maxillofac Implants (1997) 0.95
Osteoporosis in patients undergoing lung transplantation. Eur Respir J (1996) 0.95
Bone mineral mass and calcium and phosphate metabolism in young men: relationships with vitamin D receptor allelic polymorphisms. J Clin Endocrinol Metab (1999) 0.95
Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int (2012) 0.95
SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos (2013) 0.94
Bone mineral density in patients with end-stage renal failure. Am J Nephrol (1993) 0.94
LRP5 gene polymorphisms and idiopathic osteoporosis in men. Bone (2005) 0.94
Arginine increases insulin-like growth factor-I production and collagen synthesis in osteoblast-like cells. Bone (1998) 0.93
Oligo-amenorrheic long-distance runners may lose more bone in spine than in femur. Med Sci Sports Exerc (2001) 0.93
Assessment of whole-body composition with dual-energy x-ray absorptiometry. Radiology (1992) 0.93
Alterations of bone microstructure and strength in end-stage renal failure. Osteoporos Int (2012) 0.92
Temporary health effects from exposure to water-borne paints. Scand J Work Environ Health (1992) 0.92
Role of 1,25-dihydroxyvitamin D3 on intestinal phosphate absorption in rats with a normal vitamin D supply. J Clin Invest (1977) 0.91
Epidemiology and economic burden of osteoporosis in Switzerland. Arch Osteoporos (2014) 0.91
Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin (2012) 0.91
Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelines. Osteoporos Int (1999) 0.90
Longitudinal follow-up of body composition in hematopoietic stem cell transplant patients. Bone Marrow Transplant (2005) 0.90
Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int (2012) 0.90
Socioeconomic and living conditions are determinants of hip fracture incidence and age occurrence among community-dwelling elderly. Osteoporos Int (2010) 0.89
Erythromycin stearate in acute maxillary sinusitis. Scand J Infect Dis (1975) 0.89
VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). Br J Haematol (1998) 0.89